Physician profile
Brian Powell
NPI 1245274620
$5,257.89
in general payments reported to CMS, 2019-2025
23 companies · $1,032 in 2025
The $1,032 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $839 · 2020: $446 · 2021: $179 · 2022: $820 · 2023: $1,083 · 2024: $858 · 2025: $1,032.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,966 · Education: $7.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,965.82 |
| Education | $7.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $845.65 | 2022-2025 | Miebo, Xiidra, Infuse |
| Alcon Vision LLC | $762.93 | 2019-2025 | Precision 1, Precision7, Tryptyr |
| Coopervision INC. | $501.84 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Abb Con-Cise Optical Group LLC | $499.86 | 2019-2025 | Contact Lens, Spectacle Lenses |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $411.87 | 2019-2020 | |
| Allergan, INC. | $373.31 | 2019-2022 | |
| Oyster Point Pharma, INC. | $309.27 | 2022-2025 | Tyrvaya, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $300.60 | 2024-2025 | Xdemvy |
| Abbvie INC. | $270.90 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $138.82 | 2019-2023 | |
| Dompe US, INC. | $130.61 | 2022-2023 | Oxervate |
| Horizon Therapeutics Plc | $124.38 | 2023 | Tepezza |
| Sight Sciences, INC. | $120.57 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $105.48 | 2024-2025 | |
| Optos, INC. | $79.40 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Visioneering Technologies, INC. | $77.88 | 2019 | |
| Aerie Pharmaceuticals, INC. | $48.33 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $47.66 | 2024 | |
| Lkc Technologies, INC. | $26.38 | 2025 | |
| Shire North American Group INC | $24.31 | 2019 | |
| Thea Pharma INC. | $21.63 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Kala Pharmaceuticals, INC. | $16.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Powell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.